HHS U.S.-Made Drug Plan Builds On Hospital Project To Avert Shortages

HHS is granting $354 million to an America-made initiative to avert shortages of generic drugs frequently used by hospitals to treat COVID-19 patients. The BARDA grant, which has a total potential value of $812 million, builds on an existing hospital industry project that has already prevented shortages of many drugs critical to the pandemic response. HHS’ Biomedical Advanced Research and Development Authority is paying Phlow, a U.S.-based, public benefit drug-making start-up, to produce more than a dozen drugs that treat...